VNDA vs. ALT

Last updated Jun 23, 2026

VNDA (Vanda Pharmaceuticals Inc.) and ALT (Altimmune, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, VNDA returned -6.02%/yr vs -28.57%/yr for ALT. At a 0.17 correlation, their price movements are largely independent.

Performance

VNDA vs. ALT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Vanda Pharmaceuticals Inc. (VNDA) and Altimmune, Inc. (ALT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, VNDA achieves a -31.97% return, which is significantly lower than ALT's -18.84% return. Over the past 10 years, VNDA has outperformed ALT with an annualized return of -6.02%, while ALT has yielded a comparatively lower -28.57% annualized return.

VNDA

• 1D: 3.45%
• 1M: -3.07%
• YTD: -31.97%
• 6M: -14.65%
• 1Y: 33.04%
• 3Y*: -2.73%
• 5Y*: -20.51%
• 10Y*: -6.02%

ALT

• 1D: 8.52%
• 1M: 1.03%
• YTD: -18.84%
• 6M: -29.23%
• 1Y: -58.32%
• 3Y*: -9.17%
• 5Y*: -28.96%
• 10Y*: -28.57%

*Multi-year figures are annualized to reflect compound growth (CAGR)

VNDA vs. ALT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
VNDA Vanda Pharmaceuticals Inc.	-31.97%	84.13%	13.51%	-42.90%	-52.90%	19.41%	-19.93%	-37.20%	71.91%	-4.70%
ALT Altimmune, Inc.	-18.84%	-49.93%	-35.91%	-31.61%	79.59%	-18.79%	496.83%	-8.25%	-96.55%	-47.79%

Correlation

The correlation between VNDA and ALT is 0.40, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.40
Correlation (3Y) Calculated over the trailing 3-year period	0.34
Correlation (5Y) Calculated over the trailing 5-year period	0.34
Correlation (10Y) Calculated over the trailing 10-year period	0.24
Correlation (All Time) Calculated using the full available price history since Apr 12, 2006	0.17

Over the past year, VNDA and ALT have become more correlated (0.40) than their long-term average of 0.17, meaning their price movements have been converging.

Fundamentals

Market Cap VNDA : $356.76M ALT : $364.67M
EPS VNDA : -$4.05 ALT : -$0.92
PS Ratio VNDA : 1.63 ALT : 8.06K
PB Ratio VNDA : 1.27 ALT : 1.28
Total Revenue (TTM) VNDA : $217.78M ALT : $36.00K
Gross Profit (TTM) VNDA : $154.79M ALT : -$14.92M
EBITDA (TTM) VNDA : -$146.81M ALT : -$93.48M

Return for Risk

VNDA vs. ALT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VNDA

VNDA Risk / Return Rank: 60
VNDA Sharpe Ratio Rank: 56
VNDA Sortino Ratio Rank: 61
VNDA Omega Ratio Rank: 63
VNDA Calmar Ratio Rank: 60
VNDA Martin Ratio Rank: 60

ALT

ALT Risk / Return Rank: 15
ALT Sharpe Ratio Rank: 14
ALT Sortino Ratio Rank: 20
ALT Omega Ratio Rank: 17
ALT Calmar Ratio Rank: 8
ALT Martin Ratio Rank: 16

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VNDA vs. ALT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Vanda Pharmaceuticals Inc. (VNDA) and Altimmune, Inc. (ALT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	VNDA	ALT	Difference
Sharpe ratio: Return per unit of total volatility	0.41	-0.65	+1.05
Sortino ratio: Return per unit of downside risk	1.25	-0.52	+1.77
Omega ratio: Gain probability vs. loss probability	1.18	0.91	+0.26
Calmar ratio: Return relative to maximum drawdown	0.83	-0.88	+1.71
Martin ratio: Return relative to average drawdown	1.79	-1.16	+2.96

VNDA vs. ALT - Sharpe Ratio Comparison

The current VNDA Sharpe Ratio is 0.41, which is higher than the ALT Sharpe Ratio of -0.65. The chart below compares the historical Sharpe Ratios of VNDA and ALT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

VNDA vs. ALT - Drawdown Comparison

The maximum VNDA drawdown since its inception was -98.42%, roughly equal to the maximum ALT drawdown of -99.63%. Use the drawdown chart below to compare losses from any high point for VNDA and ALT.

Drawdown Indicators

	VNDA	ALT	Difference
Max Drawdown Largest peak-to-trough decline	-98.42%	-99.63%	+1.21%
Max Drawdown (1Y) Largest decline over 1 year	-40.06%	-66.41%	+26.35%
Max Drawdown (3Y) Largest decline over 3 years	-49.25%	-81.25%	+32.00%
Max Drawdown (5Y) Largest decline over 5 years	-84.29%	-90.45%	+6.16%
Max Drawdown (10Y) Largest decline over 10 years	-89.26%	-99.63%	+10.37%
Current Drawdown Current decline from peak	-81.05%	-99.29%	+18.24%
Average Drawdown Average peak-to-trough decline	-65.11%	-78.91%	+13.80%
Ulcer Index Depth and duration of drawdowns from previous peaks	18.50%	50.09%	-31.59%

Volatility

VNDA vs. ALT - Volatility Comparison

The current volatility for Vanda Pharmaceuticals Inc. (VNDA) is 11.99%, while Altimmune, Inc. (ALT) has a volatility of 14.12%. This indicates that VNDA experiences smaller price fluctuations and is considered to be less risky than ALT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VNDA	ALT	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.99%	14.12%	-2.13%
Volatility (6M) Calculated over the trailing 6-month period	64.42%	60.60%	+3.82%
Volatility (1Y) Calculated over the trailing 1-year period	81.84%	90.63%	-8.79%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	60.53%	94.20%	-33.67%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	55.71%	149.74%	-94.03%

Dividends

VNDA vs. ALT - Dividend Comparison

Neither VNDA nor ALT has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
ALT Altimmune, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,462.31%
VNDA Vanda Pharmaceuticals Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both VNDA and ALT in my portfolio?

VNDA and ALT have a correlation of 0.40, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, VNDA or ALT?

ALT has higher volatility (14.12%) compared to VNDA (11.99%). In terms of maximum drawdown, VNDA dropped -98.42% vs ALT's -99.63%.

Which has better risk-adjusted returns?

VNDA currently has the higher Sharpe Ratio (0.41 vs -0.65), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.